Rani Therapeutics Hldgs Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.707M Beat $1.280M Estimate
Benzinga Newsdesk 1 week ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 66.67 percent increase over losses of $(0.12) per share
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 66.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $1.707 million which beat the analyst consensus estimate of $1.280 million by 33.41 percent.
